Favorable response of chronic refractory immune thrombocytopenic purpura to mesenchymal stem cells

Stem Cells and Development

Volumn 21, Issue 3, 2012, Pages 497-502

  Fang, Baijun ^a   Mai, Ling ^a   Li, Ning ^a   Song, Yongping ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA1;

ADIPOSE TISSUE; ADULT; ARTICLE; CELL THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC; SUBCUTANEOUS FAT, ABDOMINAL; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

EID: 84863011328     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2011.0231     Document Type: Article

References (44)

1. McMillan R and C Durette. (2004). Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 104:956-960. (Pubitemid 39038013)
2. Portielje JE, RG Westendorp, HC Kluin-Nelemans and A Brand. (2001). Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97:2549-2554.
3. Kuwana M, J Kaburaki and Y Ikeda. (1998). Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest 102:1393-1402.
4. Hedlund-Treutiger I, J Wahlström and G Elinder. (1998). Role of the T cell receptor in idiopathic thrombocytopenic purpura (ITP). Acta Paediatr Suppl 424:46-50. (Pubitemid 28410860)
5. Semple JW, AH Lazarus and J Freedman. (1998). The cellular immunology associated with autoimmune thrombocytopenic purpura: an update. Transfus Sci 19:245-251.
6. Cines DB and R McMillan. (2005). Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 56: 425-442. (Pubitemid 40299791)
7. Semple JW and J Freedman. (1991). Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 78:2619-2625.
8. Garcia-Suarez J, A Prieto, E Reyes, L Manzano, JL Merino and M Alvarez-Mon. (1993). The clinical outcome of autoimmune thrombocytopenic purpura patients is related to their T cell immunodeficiency. Br J Haematol 84:464-470. (Pubitemid 23224163)
9. Ware RE and TA Howard. (1994). Elevated numbers of gamma-delta (gamma delta + ) T lymphocytes in children with immune thrombocytopenic purpura. J Clin Immunol 14:237-247. (Pubitemid 24257257)
10. Crossley AR, AM Dickinson, SJ Proctor and JE Calvert. (1996). Effects of interferon-alpha therapy on immune parameters in immune thrombocytopenic purpura. Autoimmunity 24:81-100. (Pubitemid 26413862)
11. Erduran E, Y Aslan, Y Aliyazicioglu, H Mocan and Y Gedik. (1998). Plasma soluble interleukin-2 receptor levels in patients with idiopathic thrombocytopenic purpura. Am J Hematol 57:119-123. (Pubitemid 28096533)
12. Semple JW, Y Milev, D Cosgrave, M Mody, A Hornstein, V Blanchette and J Freedman. (1996). Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 87:4245-4254. (Pubitemid 26152268)
13. Panitsas FP, M Theodoropoulou, A Kouraklis, M Karakantza, GL Theodorou, NC Zoumbos, A Maniatis and A Mouzaki. (2004). Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 103:2645-2647. (Pubitemid 38393019)
14. Ogawara H, H Handa, K Morita, M Hayakawa, J Kojima, H Amagai, Y Tsumita, Y Kaneko, N Tsukamoto, Y Nojima and H Murakami. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol 71:283-288.
15. Guo C, X Chu, Y Shi, W He, L Li, L Wang, Y Wang, J Peng and M Hou. (2007). Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 27:557-562.
16. Stasi R, G Del Poeta, E Stipa, ML Evangelista, MM Trawinska, N Cooper and S Amadori. (2007). Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110:2924-2930. (Pubitemid 350006946)
17. WT Tse, JD Pendleton, WM Beyer, MC Egalka and EC Guinan. (2003). Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75:389-397. (Pubitemid 36222968)
18. Krampera M, S Glennie, J Dyson, D Scott, R Laylor, E Simpson and F Dazzi. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigenspecific T cells to their cognate peptide. Blood 101:3722-3729. (Pubitemid 36857965)
19. Pérez-Simón JA, S Tabera, ME Sarasquete, M Díez-Campelo, J Canchado, LI Sánchez-Abarca, B Blanco, I Alberca, C Herrero-Sánchez, C Canizo and JF San Miguel. (2009). Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy 11:698-705.
20. Aggarwal S and MF Pittenger. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822. (Pubitemid 40223708)
21. Fang B, YP Song, LM Liao, Q Han and RC Zhao. (2006). Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplant 38:389-390.
22. Fang B, YP Song, N Li, J Li, Q Han and RC Zhao. (2009). Resolution of refractory chronic autoimmune thrombocytopenic purpura following mesenchymal stem cell transplantation: a case report. Transplant Proc 41:1827-1830.
23. Rodeghiero F, R Stasi, T Gernsheimer, M Michel, D Provan, DM Arnold, JB Bussel, DB Cines, BH Chong, et al. (2009). Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386-2393.
24. George JN. (2006). Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 4:1664-1672. (Pubitemid 44144790)
25. Mouzaki A, M Theodoropoulou, I Gianakopoulos, V Vlaha, MC Kyrtsonis and A Maniatis. (2002). Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood 100:1774-1779. (Pubitemid 34925156)
26. JB Bussel, D Provan, T Shamsi, G Cheng, B Psaila, L Kovaleva, A Salama, JM Jenkins, D Roychowdhury, B Mayer, N Stone and M Arning. (2009). Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 373:641-648.
27. Kuter DJ, JB Bussel, RM Lyons, V Pullarkat, TB Gernsheimer, FM Senecal, LM Aledort, JN George, CM Kessler, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. (2008). Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a doubleblind randomised controlled trial. Lancet 371:395-403. (Pubitemid 351181334)
28. Garcia-Chavez J, A Majluf-Cruz, L Montiel-Cervantes, MG Esparza and J Vela-Ojeda; Mexican Hematology Study Group. (2007). Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol 86:871-877.
29. Saleh MN, J Gutheil, M Moore, PW Bunch, J Butler, L Kunkel, AJ Grillo-López and AF LoBuglio. (2000). A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 27:99-103. (Pubitemid 32164602)
30. Medeot M, F Zaja, N Vianelli, M Battista, M Baccarani, F Patriarca, F Soldano, M Isola, S De Luca and R Fanin. (2008). Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. Eur J Haematol 81:165-169.
31. Marmont AM, MT van Lint, D Occhini, T Lamparelli and A Bacigalupo. (1998). Failure of autologous stem cell transplantation in refractory thrombocytopenic purpura. Bone Marrow Transplant 22:827-828. (Pubitemid 28488331)
32. Huhn RD, PF Fogarty, R Nakamura, EJ Read, SF Leitman, ME Rick, J Kimball, A Greene, K Hansmann, et al. (2003). High-dose cyclophosphamide with autologous lymphocytedepleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 101:71-77. (Pubitemid 36025889)
33. Elli E, M Parma, P Perseghin, M Dassi, E Terruzzi, D Belotti, P Pioltelli and EM Poglian. (2007). Successful treatment with T-depleted autologous peripheral blood stem cell transplantation of refractory chronic autoimmune thrombocytopenic purpura. Haematologica 92:e7-e8.
34. Lim SH, J Kell, A al-Sabah, W Bashi and R Bailey-Wood. (1997). Peripheral blood stem-cell transplantation for refractory autoimmune thrombocytopenic purpura. Lancet 349:475. (Pubitemid 27077835)
35. Skoda RC, A Tichelli, A Tyndall, T Hoffmann, S Gillessen and A Gratwohl. (1997). Autologous peripheral blood stem cell transplantation in a patient with chronic autoimmune thrombocytopenia. Br J Haematol 99:56-57. (Pubitemid 27461327)
36. Andersson J. (1998). Cytokines in idiopathic thrombocytopenic purpura (ITP). Acta Paediatr Suppl 424:61-64. (Pubitemid 28410864)
37. Yoshimura C, S Nomura, M Nagahama, Y Ozaki, H Kagawa and S Fukuhara. (2000). Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura. Eur J Haematol 64:219-224. (Pubitemid 30186778)
38. Andersson PO, D Stockelberg, S Jacobsson and H Wadenvik. (2000). A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol 79:507-513.
39. Andersson PO, A Olsson and H Wadenvik. (2002). Reduced transforming growth factor-beta1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura. Br J Haematol 116:862-867. (Pubitemid 34227008)
40. Agarwal SK and GD Marshall Jr. (2001). Dexamethasone promotes type 2 cytokine production primarily through inhibition of type 1 cytokines. J Interferon Cytokine Res 21:147-155. (Pubitemid 32679482)
41. Wang T, H Zhao, H Ren, J Guo, M Xu, R Yang and ZC Han. (2005). Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 90:914-923. (Pubitemid 41020294)
42. Fang B, Y Song, N Li, J Li, Q Han and RC Zhao. (2009). Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation. Ann Hematol 88:261-266.
43. Ringdén O, M Uzunel, I Rasmusson, M Remberger, B Sundberg, H Lönnies, HU Marschall, A Dlugosz, A Szakos, et al. (2006). Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81:1390-1397. (Pubitemid 43847148)
44. Le Blanc K, F Frassoni, L Ball, F Locatelli, H Roelofs, I Lewis, E Lanino, B Sundberg, ME Bernardo, et al.; Developmental Committee of the European Group for Blood and Marrow Transplantation. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579-1586. (Pubitemid 351626841)